Please ensure Javascript is enabled for purposes of website accessibility

Why Sangamo BioSciences' Shares Are Soaring Higher Today

By Todd Campbell - Sep 10, 2015 at 3:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sangamo plans to initiate a new hemophilia B clinical study early next year.

Source: Sangamo BioSciences

What: News that Sangamo BioSciences (SGMO 0.95%) plans to kick-off a phase 1 study to evaluate a gene-editing treatment for hemophilia B sent shares higher by 18% today.

So what: Sangamo BioSciences is a clinical stage company developing gene-editing therapies to address a variety of disease.

Currently, Sangamo BioSciences' most developed program focuses on treating HIV, but following the company's announcement, investors may want to consider the potential that gene editing may have in treating hemophilia B, too.

Previously, Sangamo BioSciences had licensed research into applying its technology to hemophilia B to Shire, but the company has since reacquired rights to that program with a goal of moving it into human trials soon.

Since a key advisory committee has given its OK to Sangamo BioSciences' phase 1 study protocol, Sangamo BioSciences plans to file an investigational new drug application for its hemophilia B candidate by the end of this year and to begin enrolling patients in its phase 1 trial early next year.

Now what: Up until now, Sangamo BioSciences' biggest opportunity has been in addressing HIV. It's currently conducting phase 2 trials of SB-728-T as a way to mimic natural HIV immunity by altering genes so that they produce non-working CCR5 proteins used by HIV to infect cells.

Adding a hemophilia B program to the mix opens up an additional commercial market for Sangamo BioSciences to target, which diversifies some risk. However, investors should recognize that Sangamo BioSciences is losing a lot of money (including $12 million in Q2 alone) and that losses will climb once the hemophilia B trials begin.

Since Sangamo BioSciences is years away from potentially having a commercial product on the market and losses are expected to mount, it's a high risk investment that investors should approach cautiously -- at least until there's positive data to back up today's enthusiasm. 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sangamo Therapeutics Stock Quote
Sangamo Therapeutics
SGMO
$6.39 (0.95%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.